Talk:Selective internal radiation therapy
 | This article is rated C-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
| |||||||||||
Merge with Brachytherapy edit
Renaming article | Assisted by Citation bot edit
I propose renaming this article to either radioembolization or transarterial radioembolization(TARE) and providing a redirect for the Selective internal radiation therapy link. Both of these two terms are used much more commonly than "SIRT",[1][2][3][4][5][6] which itself is a rather vague (how is this vs brachytherapy?) Dr G (talk) 20:21, 8 August 2017 (UTC)
References edit
- ^ Kim, Hyo-Cheol (25 June 2017). "Radioembolization for the treatment of hepatocellular carcinoma". Clinical and Molecular Hepatology. 23 (2): 109–114. doi:10.3350/cmh.2017.0004.
- ^ Gbolahan, Olumide B.; Schacht, Michael A.; Beckley, Eric W.; LaRoche, Thomas P.; O’Neil, Bert H.; Pyko, Maximilian (April 2017). "Locoregional and systemic therapy for hepatocellular carcinoma". Journal of Gastrointestinal Oncology. 8 (2): 215–228. doi:10.21037/jgo.2017.03.13.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ . doi:10.1016/j.jhep.2017.03.007.
{{cite journal}}: Cite journal requires|journal=(help); Missing or empty|title=(help) - ^ Pesapane, F.; Nezami, N.; Patella, F.; Geschwind, J. F. (16 March 2017). "New concepts in embolotherapy of HCC". Medical Oncology. 34 (4). doi:10.1007/s12032-017-0917-2.
- ^ Braat, Manon N.G.J.A.; van Erpecum, Karel J.; Zonnenberg, Bernard A.; van den Bosch, Maurice A.J.; Lam, Marnix G.E.H. (February 2017). "Radioembolization-induced liver disease". European Journal of Gastroenterology & Hepatology. 29 (2): 144–152. doi:10.1097/MEG.0000000000000772.
- ^ Sacco, Rodolfo; Conte, Caterina; Tumino, Emanuele; Parisi, Giuseppe; Giacomelli, Luca; Metrangolo, Salvatore; Bresci, Giampaolo; Cabibbo, Giuseppe; Marceglia, Sara; Eggenhoffner, Roberto (July 2016). "Transarterial radioembolization for hepatocellular carcinoma: a review". Journal of Hepatocellular Carcinoma. Volume 3: 25–29. doi:10.2147/JHC.S50359.
{{cite journal}}:|volume=has extra text (help)CS1 maint: unflagged free DOI (link)
How it is even possible considering time constraints? edit
Considering the extremely short half-life of Y90/ H166 isotopes how can the process work in practice? E.g. with the 3 mentioned manufacturers based in Australia, Canada and Japan respectively and the lack of faster-than-sound transportation since the demise of Concorde (plus time spent on packaging, export-import bureaucracy, preparations for use at the destination hospital, etc.) how can say european patients receive the injection before much of the activity decays to base elements? The current article tells none about that aspect. 94.21.160.64 (talk) 20:55, 2 May 2023 (UTC)